AIDS Treatment News - 1996

• AIDS Treatment News - 1996
• Issue #238
• Getting Your Insurer to Cover New HIV Treatments: A Crash Course
• CD8 Cells: Suppressive Factors Discovered
• AZT plus 3TC Combination Results Published
• Opportunistic Infection Prevention: National Video Symposium, January 11
• San Francisco: Cryptosporidiosis Water Warning
• Computer Censorship Update
• Activist Groups and PWA Coalitions, U.S. and Canada
• Buyers' Clubs and Other Suppliers


• Issue #239
• NTZ: Cryptosporidiosis New Treatment
• Viral Load: New Confirmation from Major Delavirdine Studies
• Protease Inhibitor Update: Treatment Combination Strategies
• Ritonavir: Expanded Access Begins, Warning on Drug Interactions
• Stanford NAC Study, San Francisco, Needs to Contact Screened Applicants and Participants for Followup
• Needle Exchange: Experts Deplore Shalala Remarks
• Retroviruses Conference Notes
• DHEA and AIDS
• DHEA Clinical Experience: Interview with Jon Kaiser, M.D.


• Issue #240
• Protease Inhibitors at Retroviruses Conference
• Protease Inhibitors in Human Testing: Annotated List
• Ritonavir (Abbott Protease Inhibitor) Proves Survival Benefit in Late-Stage AIDS
• Agouron Starts Phase III Protease Inhibitor Studies
• Vancouver International Conference: Community Booths Deadline Extended
• FDA Antiviral Advisory Committee Meetings
• Prisoners: Send Address Updates; Contacting Organizations
• NMAC Skills Building Conference in South Africa: Facilitators Wanted
• Computer Censorship Law, ACLU Test Case, Begin February 8


• Issue #241
• Merck Protease Inhibitor: More News from Retroviruses Conference
• d4T Plus ddI Antiviral Results
• Growing Crisis in Paying for Care
• AB 9: California Bill Would End County Mandate for Last-Resort Care, Including Communicable Diseases
• Press Gag Rules at AIDS Conference


• Issue #242
• Curcumin: Clinical Trial Finds No Antiviral Effect
• Protease Inhibitor Approvals: Will People Be Cut Off Drug? Followup Studies Proposal Needs Support
• Rolipram: Antidepressant Used in Europe and Japan Might Have Promise Against TNF, HIV
• Study Finds AIDS Patients Live Longer When Their Doctors Have More Experience Treating HIV
• Protease Inhibitors at Retroviruses Conference: Agouron's Results
• Retroviruses Conference: Obtaining Abstracts
• DHEA: Threat to Access?


• Issue #243
• Indinavir (Crixivan«), Merck Protease Inhibitor, Approved
• Ritonavir (NORVIR(TM)), Abbott Protease Inhibitor, Approved
• Protease Inhibitors at FDA Advisory Hearings
• FDA Antiviral Hearings: Community Perspectives
• FDA Hearings: For More Information
• Human Growth Hormone Not Recommended for Approval on Narrow Advisory Panel Vote
• Consensus Statement on the Further Development of Protease Inhibitors And Human Growth Hormone
• AIDS and Alternative Medicine, Seattle, April 28


• Issue #244
• San Francisco: 3TC Available Now to Residents through ADAP Program
• Protease Inhibitors: Patient Education Critical
• Indinavir (Crixivan«) Access and Distribution
• AIDS Research at NIH: Study Panel Issues Major Report
• Viral Load: Inconclusive FDA Hearing
• AZT, ddI, and ddC Combinations at FDA Advisory Hearing
• Cidofovir Recommended for Approval for CMV Retinitis
• California: Clinical Trials Computer Service Now Available Statewide
• San Francisco Protest Against Meeting Disruptions
• California: AB 2812 Would Outlaw Anonymous Testing
• AIDS Medications Needed Abroad


• Issue #245
• Protease Inhibitors: Ritonavir and Saquinavir Combination Trial Recruiting -- Seven U.S., Canada Sites Including San Fran
• Protease Inhibitors: Background Information
• Delavirdine Available on Expanded Access
• Sinusitis: Helpful Background, Treatment Article
• Chinese Medicine: Qigong Exercise Tape Available
• rGP-160 Treatment Vaccine (VaxSyn): Canadian Study Finds No Benefit
• FDA Reform in Congress: Interview with Peter Barton Hutt
• FDA Reform in Congress: FDA's Concerns
• Vancouver Conference: Make Travel Plans Now. Focus, Program, and Satellite Meetings
• Crixivan« Price Break for Cash Customers: $97 Per Month Less, If You Ask


• Issue #246
• Saquinavir: Combination Shows Survival Benefit; New Formulation Trial Recruiting
• Improved HIV Survival Indicates Effect of Therapy
• Kaposi's Sarcoma: DaunoXome« Approved
• Crixivan« Price: Behind the Reduction
• California: 3TC Now Available through ADAP
• Women and HIV: Conference Calls May 14, 15, on Treatment Concerns
• Alternative Treatments for HIV: Nationwide Survey Seeks Users
• Federal Policy: Ryan White, OAR, Testing Newborns
• AIDSWatch 1996: National Lobbying Days in Washington, May 19-21
• Paris Conference on NAC, Similar Therapeutic Approaches, May 21-23
• Vancouver Conference Satellite Meetings, Part II


• Issue #247
• NIH Scientists Find Cofactor for HIV Entry
• World Medicine and Western Medicine: The Missing Dialog -- Interview, Kaiya Montaocean, Co- Director, Center for Natural
• Workshop on Traditional Healing and Policy, June 13 Near Washington, D.C.
• AIDS TREATMENT NEWS Back Issues on Web
• Best Internet, Computer Sites on AIDS: Request for Information
• Computer Communication in Developing Countries: Request for Information
• AIDS and Media in Developing Countries: Request for Information
• Pharmaceutical Contributions and AIDS Organizations: Request for Input
• AIDS TREATMENT NEWS Policy on Pharmaceutical-Company Revenue


• Issue #248
• Viral Load Approved; Free Test Offered to All in U.S. with HIV
• Viral Load: New Recommendations for Clinical Practice
• Viral Load: New Proof of Importance for Disease Staging and Prognosis
• Op Ed: Viral Load FDA Approval Delays
• PMPA: New Information
• 3TC: Glaxo Wellcome Broadens Patient Assistance
• Prison: California Conference on HIV and Prison Issues, Oakland, June 27
• AIDS TREATMENT NEWS New Index Available
• Activist Communications, Activities at Vancouver Conference
• "Access for All": Communication Strategy Proposal for Activists at International Conference


• Issue #249
• New Optimism on Controlling HIV Infection
• Internet Free Speech Wins Court Test
• Azithromycin Approved for Once-Weekly MAC Prophylaxis
• Nevirapine Recommended for Approval
• Free Viral Load Tests: Remember to Dial 1 Before 888
• Needlestick Exposure: CDC Recommends Three-Drug Regimen
• AIDS and Alternative Medicine: A Journalist's Perspective


• Issue #250
• Cryptosporidiosis: NTZ Available at Buyers' Club; Customs Holds 2nd Shipment
• NAC: First Controlled Trial, Positive Results
• Nevirapine Approved
• Vancouver Conference: Each Day Summarized Nightly on World Wide Web
• SCIENCE Publishes Major AIDS Issue June 28; Full Text on Web
• CMV RETINITIS AND TREATMENT CME Course on World Wide Web
• Delavirdine Expanded Access Program Information on World Wide Web
• West Hollywood: AIDS and Chinese Medicine Conference, July 25-28
• Neuropathy: Nutrient Therapies
• World Wide Web: AIDS TREATMENT NEWS Lists Over 100 Sites


• Issue #251
• Vancouver in Perspective
• New View of Antiretroviral Treatment: Illustrations from
• Expert Panel's New Recommendations for Antiviral Treatment
• After Vancouver: Documenting Improved Survival
• Other Vancouver News


• Issue #252
• Editorial: Time to End the Death Trials
• 3TC: Combination Trial Stopped Early As Clinical Benefit Shown
• ADAP Treatment-Access Emergency -- Interview with William Arnold, ADAP Working Group
• Reminder: Free Viral Load Testing From Roche, Only Until August 16
• San Francisco Area: "Highlights from Vancouver" at Kaiser Oakland, August 20
• DHEA: Modest Viral Load Reduction in Patients
• San Francisco Cannabis Buyers' Club Raided Aug. 4


• Issue #253
• Nelfinavir Protease Inhibitor Study Recruiting
• Five-Drug or Six-Drug Antiretroviral Therapy -- Conversation with Steven Scheibel, M.D.
• 1592 -- New Experimental Antiretroviral
• Note to Readers
• Medical Marijuana: California Update
• Calendar of AIDS Research and Treatment Meetings, Late 1996 and Beyond


• Issue #254
• Human Growth Hormone Approved for Wasting
• ddI plus d4T
• Ritonavir Plus Saquinavir: Two Trials With Different Results
• CKR-5 -- Understanding the News
• HIV Sensitivity Testing: Organizing for Access
• Register to Vote: Time Running Out
• AIDS TREATMENT NEWS Associates (ATNA) Receives Nonprofit Status


• Issue #255
• Retroviruses Conference Sets January 22-26 1997 Meeting Dates: Abstract Deadline October 16
• Nelfinavir (Viracept(TM)) Expanded Access Announced
• ICAAC Conference AIDS Overview -- Available by Toll-Free Phone Call
• Washington AIDS Events: Major Demonstrations October 11, 12, and 13
• Benefits Planning -- What You Must Know: Interview with Daniel Fortuno, AIDS Benefits Counselors


• Issue #256
• Grassroots Organizing by Internet: An Example
• CKR-5: New Study Confirms Some Do Not Get HIV
• Ritonavir and Saquinavir Combination: 12-Week Data at ICAAC
• Pharmaceutical Industry Sues to Stop Discount Pricing to Clinics
• Congress, Late Sept. 1996: Funding, ADAP, Immigration
• 3TC Clinical Benefit: More Data Presented
• CMV Information: Print, Online, Phone, Video
• Viral Load Seminars for Physicians: Late October Dates in U.S. Cities
• Viral Load Overview from Treatment Action Group
• Washington, October 7: Promoting Treatment, Care in Developing Countries
• Benefits: San Francisco Training, November 1


• Issue #257
• Medical Marijuana: The State of the Research
• Marijuana and Chocolate
• Large Combination Trials with AZT, ddI, ddC: Results Published
• Viral Load Access Consensus Statement
• Viral Load Seminars for Physicians -- Rescheduled
• PhRMA Drops Lawsuit on Government Drug Pricing
• Benefits Planning: What You Must Know (Part II)


• Issue #258
• HCG: New Kind of KS Treatment?
• IL-2: Controlled Trial Finds Major CD4 Increases
• NTZ for Cryptosporidiosis: Larger Expanded Access; Buyers' Club/FDA Conflict
• International Treatment Access and Research, How You Can Help -- Interview with Dr. Peter Piot of UNAIDS
• Retroviruses Conference -- Some Scholarships Available
• Starting and Changing HIV Treatment: Conference Call Nov. 5, Recording Later
• TREATMENT ISSUES Article on New Therapies After Protease Inhibitors
• AIDSACT, New Email List for Activists
• Hepatitis C: Protease Structure of Virus Published
• Bioethics: Major Meetings in San Francisco, November 20-25


• Issue #259
• Birmingham UK Drug Therapy Conference -- Early Report
• Federal Team Developing Treatment Principles for HIV Infection
• 1592: Two Studies Recruiting
• The New Antiretroviral Arsenal
• Medical Marijuana Wins in California and Arizona
• FDA Internet Regulation? Public Comment Accepted until December 16
• AZT Twice-Daily Tablets Approved; Dosing Concerns
• Retroviruses Conference: Press Deadline December 6
• Qigong Program on San Francisco KQED TV, Beginning December 7


• Issue #260
• Buyers' Club Crisis -- Challenge for AIDS Community
• Fewer AIDS Deaths: San Francisco Information
• FDA Advisory Committee Deadlocks on Delavirdine
• Albendazole Free from Buyers' Club
• Books: IMPURE SCIENCE: AIDS, ACTIVISM, AND THE POLITICS OF KNOWLEDGE, by Steven Epstein, University of California Press,
• Buyers' Clubs List, December 1996
• AIDS TREATMENT NEWS Reader Survey


• Issue #261
• Viral Load Seminars in January and February, Eight U.S. Cities
• d4T+AZT -- Unexpected CD4 Drop Seen in Study
• 1592: Consensus Letter on Access to New Glaxo Drug
• Call for Research on Better Use of Existing Drugs in Advanced Disease
• National Conference on Women and HIV -- Late Breaker Deadline March 21
• Geneva AIDS Conference Seeks Community Planning Coordinator
• Vaccine Report Available
• Reminder: AIDS TREATMENT NEWS Reader Survey
• Medical Marijuana: Legal Issues for Physicians, Others
• Marijuana and Research
• AIDS TREATMENT NEWS 28-Page Index
• AIDS TREATMENT NEWS Index, 1996

All information on AIDS.ORG is designed to support, but not replace your relationship with your doctor, and is intended soley for educational or research purposes. Any and all personal information you may provide us with is never released to anyone at any time. Your privacy and trust is extremely important to us.

• News
• Topics
• Experience
• Donate
• About Us

• Headlines
• AIDS Treatment News